Malignant peripheral nerve sheath tumor development during MEK inhibitor treatment: A pre-clinical study and a clinical case series.
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Nov 2026 · 1 min read
In brief
In brief
This study investigates the paradoxical development of malignant peripheral nerve sheath tumors in NF1 patients during MEK inhibitor therapy with selumetinib. Combining preclinical models with clinical case series, the research examines potential mechanisms of treatment-emergent malignant transformation in this high-risk population.
Written by the GCMD Library team from the article.
Statements in this article
People with Neurofibromatosis type 1 are at risk of developing benign and malignant peripheral nerve sheath tumors.
In NF1, the overall lifetime risk of MPNST is estimated at 8%-13%.
Increased MPNST risk is associated with specific germline mutations and larger benign tumor burden in NF1.
Selumetinib, a mitogen-activating protein kinase kinase inhibitor, was the first FDA-approved therapy for NF1.